West Virginia University
Protea announces new bioanalytical services

A graduate tenant offers new technology.

Graduate tenant’s drug passes human trial test

Protea Biosciences has completed a human trial on a new drug that would be used to treat chronic pancreatic disease.

Protea prepares to market new instrument

A company in Morgantown is using a new type of technology to shorten the time it takes to test tissue samples for proteins.

Protea founder part of WVU roundtable with Sen. Jay Rockefeller

Steve Turner, founder and CEO of Protea Biosciences, suggested exposing kids to scientific equipment and facilities at a younger age.

Graduate tenant develops new technology

Protea Biosciences’ technology virtually eliminates IgG from serum samples.

Video from WBOY on Protea’s new partnership

WBOY Channel 12 featured WVUBI graduate tenant Protea Biosciences on the nightly news.

Protea Biosciences and Mayoly-Spindler Announce Human Clinical Trial for New Biopharmaceutical

Protea Biosciences, Inc. announced today that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has commenced a Phase I/IIA human clinical trial for a new recombinant Lipase.

Protea Biosciences Continues to Make New Developments

Protea Biosciences continues to revolutionize the science of protein analysis.

Protea Biosciences Recieves Patent

Protea Biosciences continues to research and develop breakthrough medical technologies.

Protea Biosciences Press Release

Press release about Protea Biosciences